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Abstract. 
 
There is increasing evidence for a central 
role in mammalian apoptosis of the interleukin-1
 
b
 
–
converting enzyme (ICE) family of cysteine proteases, 
homologues of the product of the nematode “death” 
gene, 
 
ced-3.
 
 Ced-3 is thought to act as an executor 
rather than a regulator of programmed cell death in the 
nematode. However, it is not known whether mamma-
lian ICE-related proteases (IRPs) are involved in the 
execution or the regulation of mammalian apoptosis. 
Moreover, an absolute requirement for one or more 
IRPs for mammalian apoptosis has yet to be estab-
lished. We have used two cell-permeable inhibitors of 
IRPs, Z-Val-Ala-Asp.fluoromethylketone 
(ZVAD.fmk) and 
 
t
 
-butoxy carbonyl-Asp.fluorometh-
ylketone (BD.fmk), to demonstrate a critical role for 
IRPs in mammalian apoptosis induced by several dis-
parate mechanisms (deregulated oncogene expression, 
ectopic expression of the Bcl-2 relative Bak, and DNA 
damage–induced cell death). In all instances, 
ZVAD.fmk and BD.fmk treatment inhibits characteris-
tic biochemical and morphological events associated 
with apoptosis, including cleavage of nuclear lamins 
and poly-(ADP-ribose) polymerase, chromatin conden-
sation and nucleosome laddering, and external display 
of phosphatidylserine. However, neither ZVAD.fmk 
nor BD.fmk inhibits the onset of apoptosis, as charac-
terized by the onset of surface blebbing; rather, both 
act to delay completion of the program once initiated. 
In complete contrast, IGF-I and Bcl-2 delay the onset 
of apoptosis but have no effect on the kinetics of the 
program once initiated. Our data indicate that IRPs 
constitute part of the execution machinery of mamma-
lian apoptosis induced by deregulated oncogenes, DNA 
damage, or Bak but that they act after the point at 
which cells become committed to apoptosis or can be 
rescued by survival factors. Moreover, all such blocked 
cells have lost proliferative potential and all eventually 
die by a process involving cytoplasmic blebbing.
 
A
 
poptosis
 
 is an innate cell suicide mechanism in-
voked in disparate situations, both physiological
and pathological, to ablate unwanted, damaged,
or potentially neoplastic cells. Apoptosis is classically de-
fined by a characteristic series of morphological changes in
the doomed cell, including membrane blebbing, cell
shrinkage, chromatin condensation, and DNA cleavage,
and culminating in fragmentation of the cell into mem-
brane-bound apoptotic bodies whose surfaces express po-
tent triggers for phagocytosis. A cell suicide program ap-
pears to have arisen early in metazoan evolution and its
basal machinery has been substantially conserved. The key
genetic protagonists of programmed cell deaths in the
nematode worm, 
 
Caenorhabditis elegans
 
, are two “killer”
genes, 
 
ced-3
 
 and 
 
ced-4
 
, that are required for the execution
of the death program and 
 
ced-
 
9, the “protector” gene,
which mitigates the actions of the killer genes. 
 
ced-9
 
 and
 
ced-3
 
 each have numerous mammalian homologues: 
 
ced-9
 
is related structurally and functionally to the family of
death-regulating genes of which the oncogene 
 
bcl-2
 
 is the
prototype (Hengartner and Horvitz, 1994) and the 
 
ced-3
 
product is structurally and functionally homologous to a
class of mammalian cysteine proteases, of which the proto-
type is the interleukin-1
 
b
 
–converting enzyme (ICE)
 
1
 
 (Yuan
et al., 1993). To date, no vertebrate homologue for 
 
ced-4
 
has been identified.
ICE was originally described as the cysteine protease re-
quired for the cleavage of pro-interleukin-1
 
b
 
 at Asp
 
116
 
-
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1.
 
 Abbreviations used in this paper
 
: 4-OHT, 4-hydroxytamoxifen; BD.fmk,
 
t-
 
butoxy carbonyl-Asp.fluoromethylketone; FLICE, FADD-like ICE; ICE,
interleukin-1
 
b
 
-converting enzyme; IGF, insulin-like growth factor; IRP,
ICE-related protease; MACH, MORT1-associated CED-3 homologue;
MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; PARP,
poly-(ADP-ribose) polymerase; RT, room temperature; ZVAD.fmk, ben-
zyloxycarbonyl-Val-Ala-Asp(
 
O-
 
methyl)-fluoromethylketone.
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Ala
 
117
 
 to generate the active cytokine (Cerretti et al., 1992;
Thornberry et al., 1992). ICE is but one of an emerging
family of ICE-related proteases (IRPs), whose known
members include Ich-1/Nedd-2 (Kumar et al., 1994; Wang
et al., 1994), Ich-2/TX/ICE
 
rel
 
II (Faucheu et al., 1995; Ka-
mens et al., 1995; Munday et al., 1995), CPP32/Apopain/
Yama (Fernandes-Alnemri et al., 1994; Nicholson et al.,
1995; Tewari et al., 1995), Mch2 (Fernandes-Alnemri et al.,
1995
 
a
 
), Mch3/ICE-LAP-3 (Duan et al., 1996
 
a
 
; Fernandes-
Alnemri et al., 1995
 
b
 
), ICE-LAP-6 (Duan et al., 1996
 
b
 
),
ICE
 
rel
 
III/TY (Faucheu et al., 1995; Munday et al., 1995)
and FADD-like ICE/MORT1-associated CEP-3 homo-
logue (FLICE/MACH) (Boldin et al., 1996; Muzio et al.,
1996). Of these, ICE, CPP32
 
b
 
, Mch2, and FLICE/MACH
have been directly implicated in apoptosis: FLICE/MACH
(Boldin et al., 1996; Muzio et al., 1996) and ICE (Enari et al.,
1995; Kuida et al., 1995) are required for induction of apop-
tosis through the TNF-R1 and CD95/Fas signaling path-
ways. FLICE/MACH is directly activated upon ligand
binding to either TNF-R1 or CD95/Fas receptors (Boldin
et al., 1996; Muzio et al., 1996), and ICE activity is re-
quired (Enari et al., 1995; Los et al., 1995) for downstream
activation of a CPP32
 
b
 
-like protease necessary for apop-
tosis to occur (Enari et al., 1996). CPP32
 
b
 
 has also been
implicated as a general component of the apoptotic pro-
gram (Nicholson et al., 1995; Tewari et al., 1995) and is a
component of prICE, a proteolytic extract derived from
apoptotic chick cells that induces condensation and frag-
mentation of interphase nuclei (Lazebnik et al., 1995
 
a
 
).
Mch2 cleaves nuclear lamins (Orth et al., 1996; Takahashi
et al., 1996), an activity also present in prICE (Lazebnik
et al., 1995
 
b
 
).
All members of the ICE-related protease family share a
predilection for cleavage of their substrates after an aspar-
tate residue at the P1, usually followed by a small residue
at the P1
 
9
 
 position, and all are synthesised as proenzymes
that are activated by cleavage at critical aspartate residues
that themselves conform to the substrate consensus for
ICE family proteases. Thus, the IRPs are presumed to ex-
ist within hierarchies of auto- and trans-cleavage. For ex-
ample, proICE can be activated by auto-cleavage (Thorn-
berry et al., 1992), and proCPP32
 
b
 
 can be activated by
ICE (Tewari et al., 1995) as well as by the cytotoxic T cell
granule serine protease granzyme B (Darmon et al., 1995).
ICE-related protease processing releases an NH
 
2
 
-terminal
prodomain of varying length in different IRPs and cleaves
the remaining polypeptide to yield two subunits (p20 and
p10 for human ICE) that form the active (p20:p10)
 
2
 
 en-
zyme (Walker et al., 1994; Gu et al., 1995
 
b
 
). The larger
subunit contains the catalytic cysteine, but both subunits
are required for enzyme activity.
Some clues as to how activated IRPs trigger apoptosis
come from identification of potential IRP targets. CPP32
 
b
 
cleaves poly-(ADP-ribose) polymerase (PARP) (Lazeb-
nik et al., 1994; Gu et al., 1995
 
a
 
) and DNA-dependent pro-
tein kinase (Casciola Rosen et al., 1995), both involved in
aspects of DNA damage sensing and repair, whereas Mch2
cleaves nuclear lamins (Orth et al., 1996; Takahashi et al.,
1996). Other targets of various IRPs are the sterol regula-
tory element–binding proteins SREBP-1 and SREBP-2
(Wang et al., 1995), the 70-kD protein of the U1-snRNP
(Casciola Rosen et al., 1994), PKC
 
d
 
 (Emoto et al., 1995),
and various components of the cytoskeleton such as actin
(Mashima et al., 1995) and Gas2, a component of the mi-
crofilament system (Brancolini et al., 1995). However, it is
unclear which, if any, of these targets is responsible for the
cell blebbing, condensation, and fragmentation that char-
acterizes apoptosis.
In the nematode, genetic evidence favors the notion that
the IRP Ced-3 is part of the “execution machinery” of
nematode cell death since, in 
 
ced-3–
 
deficient mutants, no
cell deaths occur (Ellis and Horvitz, 1986). However, the
increased complexity and potential hierarchical relation-
ships between mammalian IRPs make it unclear which
proteases might act as executors of apoptosis and which
might serve to regulate those executors. It is also unclear
whether certain mammalian IRPs comprise a “final and
obligate common pathway” activated by all triggers of
mammalian apoptosis.
One way to approach these questions is to use inhibitors of
IRPs based upon the preferred peptide substrate specificity
of these enzymes. In this paper, we use two broad-spectrum
cell permeable IRP inhibitors—benzyloxycarbonyl-Val-
Ala-Asp(
 
O
 
-methyl)-fluoromethylketone (ZVAD.fmk) and
 
t
 
-butoxy carbonyl-Asp.fluoromethylketone (BD.fmk)—to
demonstrate that IRPs are involved in mammalian apop-
tosis induced by disparate signals. Most importantly, how-
ever, we show that inhibition of IRPs blocks only part of
the classical apoptotic program, generating doomed cells
that are arrested before the program has completed.
 
Materials and Methods
 
Cell Culture and Cell Lines
 
Rat-1 fibroblasts expressing the 
 
b
 
-oestradiol and the 4-hydroxytamoxifen
(4-OHT)–dependent conditional alleles of c-Myc (Rat-1/c-MycER and
Rat-1/c-MycER
 
Ô
 
, respectively) were isolated as described (Littlewood et al.,
1995). Rat-1 fibroblasts expressing Bak from a Gal-4 element under the
control of the 4-OHT–activatable chimeric GalER-VP16 transcription
factor (Braselmann et al., 1993) have also been described (Rat-1/Bak
cells) (Chittenden et al., 1995), as have Rat-1/c-MycER cells constitutively
expressing Bcl-2 (Rat-1/c-MycER/Bcl-2) (Fanidi et al., 1992). A further
Rat-1 cell line, constitutively expressing the adenovirus E1A (12S) protein
(Rat-1/E1A), was isolated by infection of Rat-1 cells with the recombinant
retrovirus pBabeNEO containing the entire open reading frame of 12S
E1A under the control of the virus LTR and subsequent selection and
cloning. Expression of 12S E1A was verified by immunoblotting. Rat-1
cells expressing E1A (12S) or empty vector controls were washed twice in
serum-free medium and subsequently cultured in serum-free conditions.
Cells were observed for 48 h using time lapse videomicroscopy. Rat-1/E1A
cells exhibited marked apoptosis compared to controls demonstrating the
ability of E1A to induce apoptosis in the absence of serum. Rat-1/c-
MycER
 
Ô
 
, Rat-1/c-MycER/Bcl-2, and Rat-1/E1A cell lines were main-
tained in DME supplemented with 10% FCS and 1 mg/ml gentamicin.
Rat-1/Bak cells were maintained in phenol-red–free DME supplemented
with 10% charcoal-dextran–stripped FCS and 1 mg/ml gentamicin. Cells
were selected using puromycin at 5 
 
m
 
g/ml for Rat-1/c-MycER
 
Ô
 
, neomycin
at 1 mg/ml for Rat-1/E1A cells, and with puromycin at 5 
 
m
 
g/ml and neo-
mycin at 1 mg/ml for Rat-1/Bak cells. Cells were passaged by standard
trypsinization and seeded directly onto tissue culture plastic. Cells were
serum-depleted by culture in 0.05% FCS for 48 h. Both Myc and Bak ex-
pression were induced by addition of 4-OHT to the cell cultures to a final
concentration of 100 nM.
 
Reagents and Antibodies
 
4-OHT was obtained from SEMAT (St. Albans, UK). A 1 mM stock solu-
tion in 100% ethanol was prepared, stored at 
 
2
 
20
 
8
 
C, and diluted in DME
as required. ZVAD.fmk and BD.fmk were obtained from Enzyme Sys- 
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tems Products (Dublin, CA). Stock solutions in DMSO were prepared at
50 mM, stored at 
 
2
 
80
 
8
 
C, and used as required. Etoposide/VP16, phalloi-
din, and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) were obtained from Sigma (Poole, UK). FITC-labeled annexin V
was obtained from Bender & Co. GmbH (Vienna, Austria). Secondary
antibodies and enhanced chemiluminescence were obtained from Amer-
sham International (Amersham, UK).
Polyclonal antibody to adenovirus E1A protein was the gift of Dr. N.
Jones, Imperial Cancer Research Fund, London, UK (ICRF). Polyclonal
antibody to PARP (C-2-10) was the gift of Dr. W. Earnshaw (Edinburgh
University, Scotland, UK). The anti–lamins A and C antibody (131C3)
was the gift of Dr. Y. Raymond (Institut du Cancer de Montreal, Mont-
real, Canada), together with the control antibody MOPC 21C. The actin
antibody was the gift of Dr. Fulvia Verde, ICRF.
 
Time-Lapse Videomicroscopy
 
Time-lapse videomicroscopic images were acquired on an inverted phase
contrast microscope (Diaphot; Nikon, Inc., Mellville, NY) equipped with
epifluorescence and collected on either BetaCam or sVHS video tape un-
der the control of an external animation controller (EOS Electronics AV
Ltd., Barry, Wales, UK) as described (Evan et al., 1992). Apoptotic cell
deaths were scored at the point when they were fully detached and
rounded. Cells with the “blebbing” phenotype were deemed to be alive
while they remained adherent and actively blebbing and similarly scored
as dead once fully detached and rounded.
 
Western Blotting
 
Cleavage of poly(ADPribose) polymerase, nuclear lamins A and C, and
actin was analyzed by SDS-PAGE and subsequent transfer to nitrocellu-
lose membrane (Immobilon P, Amersham International). Membranes
were blocked in TNT buffer (1% TBS, 0.5% Tween 20, and 5% skimmed
milk) for 30 min and then incubated in antibodies to PARP (Lamarre et al.,
1986), actin, or lamins A and C antibody at 4
 
8
 
C for 12 h in TNT buffer.
Membranes were washed twice in TNT and then incubated for 1 h at room
temperature (RT) with anti–mouse or anti–rabbit HRP-conjugated sec-
ondary antibody as appropriate. Finally, membranes were washed twice in
TNT buffer and once in TBS and 0.5% Tween 20, and bound antibodies
were visualized by enhanced chemiluminescence.
 
Electron Microscopy and Immunocytochemistry
 
Standard electron microscopic techniques were used as follows. Cells were
pelleted, fixed for 1 h at RT in 2.5% glutaraldehyde in Sorensens buffer,
postfixed in osmium tetroxide in the same buffer, and embedded in
Araldite resin. Sections were cut on a Reichert ultracut, stained with ura-
nyl acetate and lead citrate, and viewed on an electron microscope (EM
10 CR; Carl Zeiss, Inc., Thornwood, NY). PARP expression and localiza-
tion was determined immunocytochemically as previously described
(Lamarre et al., 1986). Briefly, cells were grown on 8-well chamber slides
and fixed with 100% methanol for 10 min at 
 
2
 
20
 
8
 
C. Fixed cells were incu-
bated with primary antibody for 60 min at RT in PBS followed by five
washes in PBS buffer containing 0.1% Tween 20. After incubation in ap-
propriate FITC-labeled secondary antibodies, cells were viewed using a
confocal microscope (model MRC 1000; BioRad Labs, Hercules, CA).
Lamins were identified immunocytochemically using anti–lamin A
 
1
 
C an-
tibody (1:100), incubated with cells previously fixed as described above,
and preblocked in 10% FCS and PBS. After three washes in PBS, cells
were incubated with secondary antibody as described above. For actin
staining, cells were fixed in 4% paraformaldehyde in PBS for 10 min,
washed in PBS at RT, and then permeabilized with 0.2% Triton in PBS
for 5 min. Cells were then rinsed in PBS and incubated with 0.1 
 
m
 
g/ml
FITC-phalloidin in PBS for 20 min at RT. Finally, cells were washed sev-
eral times in PBS, mounted, and viewed as above.
 
Assays of Cell Viability
 
Mitochondrial dehydrogenase activity, used as a marker of cell survival,
was assayed by the ability of cells to convert soluble MTT into an insolu-
ble formazan reaction product (Mosmant, 1983). 10 
 
m
 
l of MTT solution (5
mg/ml in PBS) was added to each well of a 96-well plate containing 3,000
cells in 100 
 
m
 
l of medium. The reaction was stopped after 2 h at 37
 
8
 
C by
removal of the supernatant and addition of 200 
 
m
 
l of acid propan-2-ol.
The plates were left at RT for 15 min in the dark, and absorbance differ-
ence at 570–630 nm was measured using a microplate reader and % sur-
vival calculated as (Experiment 
 
2
 
 Blank)/(Control 
 
2
 
 Blank) 
 
3
 
 100%,
where the blank is medium 
 
1
 
 MTT without cells and the Control was the
signal from wells with maximum cell survival, i.e., with serum and no 4-OHT.
Cell survival was also assayed by a direct microscopic assessment of the
proportion of cells able to exclude the vital dye, trypan blue. Rat-1/c-
MycER
 
Ô
 
 cells were grown in 3-cm tissue culture dishes, changed to se-
rum-free medium for 48 h, and then 4-OHT 
 
6
 
 ZVAD.fmk/BD.fmk was
added (time 0). At the time points indicated, cells were trypsinized and
washed in DME, and the number of trypan blue–positive cells was as-
sessed by counting a minimum of 200 cells on a hemocytometer.
 
Flow Cytometric Analysis of Cells
 
Adherent cells were trypsinised, fixed in 70% ethanol, and stained with
propidium iodide. Flow cytometric analysis was carried out on a Becton-
Dickinson (Mountain View, CA) FACSstar plus.
 
Annexin V Binding to External Phosphatidyl Serine
 
Cells undergoing apoptosis in the presence or absence of ZVAD.fmk or
BD.fmk were observed by time-lapse videomicroscopy. At the time that a
significant proportion of the cells were either apoptoptic (no ZVAD.fmk/
BD.fmk) or blebbing (plus ZVAD.fmk/BD.fmk), the culture was flooded
with FITC–annexin V. The same microscopic field as had been observed
thus far was then examined by fluorescence and phase microscopy to de-
tect bound annexin V and examine cell morphology, respectively.
 
Results
 
ZVAD.fmk and BD.fmk, Inhibitors of
ICE-related Proteases, Delay but Do Not Prevent Cell 
Death Induced by Multiple Signals
 
Apoptosis can be triggered by a wide range of influences,
including oncogene deregulation, DNA damage, and ex-
pression of killer genes. To determine the general rele-
vance of IRPs to apoptosis, we examined the effect of the
cell-permeable IRP inhibitors, ZVAD.fmk and BD.fmk,
upon apoptosis induced in Rat-1 fibroblasts by a number
of agents. Apoptosis was induced by activation of a dereg-
ulated conditional allele of c-Myc (Littlewood et al., 1995),
expression of the adenovirus protein E1A (Rao et al.,
1992), DNA damage in combination with c-Myc expres-
sion using the topoisomerase II inhibitor etoposide
(Fanidi et al., 1992), or expression of the killer member of
the Bcl-2 family, Bak (Chittenden et al., 1995). Both E1A
(Debbas and White, 1993) and etoposide (Lowe et al.,
1993) induce apoptosis via a p53-dependent mechanism;
c-Myc may act partly via p53 (Littlewood et al., manu-
script in preparation) and Bak killing is p53 independent
(T. Chittenden, unpublished data).
The Rat-1 fibroblast cell lines were induced, activated,
or treated with drug, as appropriate, in the presence or ab-
sence of ZVAD.fmk or BD.fmk. Cells were monitored by
time-lapse videomicroscopy and scored as dead when they
became detached from the substratum. Both ZVAD.fmk
and BD.fmk afforded excellent protection from apoptosis
in all cases, regardless of the trigger (data for ZVAD.fmk
shown in Fig. 1). Thus, all these triggers of apoptosis act
via a ZVAD.fmk- or BD.fmk–sensitive agent, presumably
one or more of the IRPs.
As shown in Fig. 1, the degree of protection afforded by
ZVAD.fmk or BD.fmk is profound. Nonetheless, under
the sustained pro-apoptotic influence of c-Myc, E1A, Bak,
or continuous DNA damage, all cells were eventually ob-
served to detach from the substratum, undergo partial 
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chromatin condensation, and eventually become perme-
able, even in the sustained presence of ZVAD.fmk or
BD.fmk (see below). Neither higher levels of ZVAD.fmk
or BD.fmk nor regular 24 hourly readdition of ZVAD.fmk
or BD.fmk to the culture medium was able to delay the
eventual demise of cells (data not shown), suggesting
ZVAD.fmk and BD.fmk inhibition of cell death is eventu-
ally overwhelmed or bypassed. In all cases tested, the ef-
fects of ZVAD.fmk and BD.fmk were identical. Accord-
ingly, primarily data for ZVAD.fmk is shown henceforth.
 
ZVAD.fmk Does Not Delay the Onset
of Membrane Blebbing but Blocks Completion of the 
Apoptotic Program
 
Time-lapse videomicroscopy permits observation both of
the onset and the execution of individual apoptotic events
within a cell culture. The onset of apoptosis is character-
ized by the sudden initiation of surface blebbing, together
with cytoplasmic fragmentation and exfoliation, from
which the name apoptosis derives. In fibroblastic cells, on-
set of blebbing is rapidly followed by nuclear condensation
and collapse and total cell fragmentation, a process that
typically takes between 30–60 min (Evan et al., 1992) (see
Note Added in Proof for Web information). However,
whereas an individual apoptotic event is rapid, individual
cells within a culture, undergoing apoptosis induced by ac-
tivation of c-Myc in low serum, demonstrate asynchronous
initiation of apoptosis over a prolonged period. Since such
apoptosis is cell cycle independent, the basis of this asyn-
chronicity is unclear, although its incidence is greatly af-
fected by levels of c-Myc protein and the presence of sur-
vival factors in the culture medium (Harrington et al., 1994).
Using time-lapse videomicroscopy to observe cells un-
dergoing c-Myc–induced apoptosis in the presence of ei-
ther ZVAD.fmk or BD.fmk, we were surprised to find
that neither inhibitor appears to delay the initiation of ap-
optosis within the cultures, as judged by the onset of
blebbing. Indeed, the kinetics of onset of apoptotic events
within ZVAD.fmk-treated cultures were superimposable
on those of untreated cell cultures (Fig. 2 
 
A
 
). However,
unlike untreated cells, ZVAD.fmk- or BD.fmk-treated cells
did not rapidly condense and fragment but continued to
bleb and boil for extended periods (Fig. 2 
 
B
 
). During this
extended blebbing, often lasting days, cells remain adher-
ent, exclude trypan blue, and exhibit physical activity, all
suggestive of sustained metabolism (see Note Added in
Proof for Web Information). This latter notion was sup-
ported by assaying mitochondrial activity of ZVAD.fmk-
treated cells using the MTT assay, which showed contin-
ued mitochondrial dehydrogenase activity in such cells
(Fig. 3 
 
A
 
).
Thus, ZVAD.fmk-treated cells appear to initiate apop-
tosis normally but then become arrested within the apop-
totic program. Identical results were obtained when ap-
optosis was induced by E1A, etoposide, or Bak expression
(data not shown).
 
Characterization of Apoptotic Cells Blocked
with ZVAD.fmk
 
To investigate further the ZVAD.fmk-mediated block in the
Figure 1. The cell-permeable
inhibitors of ICE-related
proteases, ZVAD.fmk and
BD.fmk, suppress apoptosis
induced by oncogenes, DNA
damage, and Bak. Rat-1 cell
cultures were observed by
time-lapse videomicroscopy
and images were collected at
the rate of 12 frames/h. At
the end of each 5-h period,
the total number of apoptotic
events (as determined by
cell detachment) thus far was
summed and plotted against
time. Rates of apoptotic
events in each culture are
shown in the presence or ab-
sence of ZVAD.fmk (100
mM). Both ZVAD.fmk and
tamoxifen (where applica-
ble) were added at time 0.
(A) Rat-1 cells expressing
c-Myc-ERÔ in the presence
(m) or absence (d) of
ZVAD.fmk. c-Myc was acti-
vated by addition of 4-OHT
(100 nM). (B) Rat-1 cells ex-
pressing Bak under the con-
trol of a GalER-VP16 promotor in the presence (m) or absence (d) of ZVAD.fmk. The GalER-VP16 chimeric transcription factor was
activated by addition of 4-OHT (to 100 nM), so inducing expression of Bak. (C) Rat-1 cells constitutively expressing the adenoviral
E1A protein in the presence (m) or absence (d) of ZVAD.fmk. (D) Rat-1 cells expressing c-MycERÔ and treated with etoposide/
VP16 (100 nM) in the presence (m) or absence (d) of ZVAD.fmk. c-Myc was again activated by addition of 4-OHT (to 100 nM). 
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death program, we examined a number of biochemical and
morphological parameters of apoptosis in the ZVAD.fmk-
treated blebbing cells. First, we examined the efficacy with
which ZVAD.fmk inhibits intracellular IRPs by examining
cleavage of known IRP substrates by a combination of West-
ern blotting and confocal immunofluorescence microscopy.
Cells were harvested from ZVAD.fmk-treated cultures in
which 50–60% of cells exhibited the continuously blebbing
phenotype as judged by time-lapse videomicroscopy (typi-
cally 24–36 h after induction of apoptosis), and cell lysates
fractionated by SDS-PAGE and electroblotted. Blots were
probed with antibodies to actin, lamins A
 
1
 
C, and PARP,
all known IRP substrates (Lazebnik et al., 1994, 1995
 
b
 
; Gu
et al., 1995
 
a
 
; Mashima et al., 1995; Oberhammer et al.,
1994), and compared with equivalent lysates from control
cultures without ZVAD.fmk. ZVAD.fmk inhibits cleavage
of all proteins for up to 48 h (Fig. 4 
 
A
 
). We also examined
the immunocytochemical distribution of actin, PARP, and
lamin staining in cells with and without ZVAD.fmk treat-
ment by immunofluorescence confocal microscopy (Fig. 4
 
B
 
). The effect of ZVAD.fmk on actin distribution within
cells was examined by staining permeabilized cells with
phalloidin-FITC. This showed ZVAD.fmk-treated cells to
be morphologically distinct from either log-phase viable or
apoptotic  cells, exhibiting very obvious cytoplasmic
blebbing (Fig. 4 
 
B
 
). ZVAD.fmk treatment prevented the
dispersal and reduction of PARP and lamin staining that is
typically observed in apoptotic cells. Thus, as reported
elsewhere (Fearnhead et al., 1995; Fletcher et al., 1995;
Slee et al., 1996), ZVAD.fmk effectively inhibits intracel-
lular cleavage of known IRP substrates.
Next, electron microscopy was performed on Rat-1/c-
MycER
 
Ô
 
 cells induced to undergo apoptosis in the presence
or absence of ZVAD.fmk (Fig. 5). 24 h after c-Myc activa-
tion in low serum, many cells in the non–ZVAD.fmk-
treated population exhibited features of classical apoptosis,
i.e., chromatin condensation, cell shrinkage, cytoplasmic
blebbing, and cell fragmentation. In contrast, although
cells from ZVAD.fmk-treated populations exhibited gross
cytoplasmic blebbing and some dilatation of the endoplas-
mic reticulum, their organelle structure was otherwise
well preserved. More remarkably, nuclei of ZVAD.fmk-
treated cells resembled those of nonapoptotic cells, with
reticular chromatin pattern bounded by intact nuclear
lamina and membrane.
 
Figure 2.
 
ZVAD.fmk and BD.fmk do not delay the onset of cell
death, but block completion of apoptosis after the onset of mem-
brane blebbing. (
 
A
 
) ZVAD.fmk does not delay onset of cell death
but extends the kinetics of individual apoptotic events. Time-
lapse videomicroscopic quantitation of onset of apoptosis in-
duced in Rat-1/c-MycER
 
Ô
 
 cells by 4-OHT (100 nM) in the pres-
ence (
 
m
 
) or absence (
 
d
 
) of ZVAD.fmk (to 100 
 
mM). Time-lapse
videomicroscopy was performed as before, but cells were scored
for initiation of membrane blebbing. (B) Both ZVAD.fmk and
BD.fmk show profound cytoplasmic blebbing 24 h after c-Myc in-
duction in the absence of serum. Rat-1/c-MycERÔ cells were se-
rum starved for 48 h before addition of 4-OHT (100 nM) with
and without 100 mM ZVAD.fmk or 5 mM BD.fmk. After 24 h,
cells were examined by light microscopy using Hoffman optics.
Both photographs show a representative field of blebbing cells
treated with either ZVAD.fmk or BD.fmk.The Journal of Cell Biology, Volume 136, 1997 220
We next examined integrity of DNA in ZVAD.fmk-
treated blebbing cells. Flow cytometric analysis demon-
strated that ZVAD.fmk suppresses the appearance of cells
with sub-G1 content of DNA characteristic of apoptotic
cells (Fig. 3 B). Consistent with this, no degradation of
DNA into typical oligonucleosomal fragments (Wyllie,
1980) was detected in DNA extracted from ZVAD.fmk-
treated cells up to 48 h after c-Myc activation (data not
shown).
Apoptosis is classically associated with loss of mem-
brane phospholipid asymmetry: inactivation of a critical
“flippase” results in expression of phosphatidylserine on
the cell surface, a signal for recognition and ingestion of
apoptotic cells by macrophages (Fadok et al., 1992). Sur-
face phosphatidylserine expression was assessed by bind-
ing of FITC-labeled annexin V and visualized by fluo-
rescence microscopy (Koopman et al., 1994). Rat-1/c-MycERÔ
cells undergoing normal apoptosis exhibited annexin V
binding, whereas no binding was detected on blebbing cells
blocked with ZVAD.fmk or live cells (Fig. 6). Thus,
ZVAD.fmk blocks apoptosis before destruction of mem-
branes, mitochondria, or loss of phosphatidylserine asym-
metry.
As discussed above, ZVAD.fmk-treated cells induced to
undergo apoptosis and exhibiting the blebbing phenotype
for several days do eventually detach and become permeable
to vital dyes. Analysis of these “late-stage” ZVAD.fmk-
treated cells revealed a ragged surface membrane, vacuolated
cytoplasm, partial chromatin condensation (although less
than in “normal” apoptotic cells), and eventual membrane
permeability (data not shown). We conclude that these
cells appear to have undergone a partial apoptotic cell death,
although this will require further characterization.
ZVAD.fmk Inhibits Apoptosis Downstream of
the Antiapoptotic Cytokine IGF-1 or the Apoptosis 
Suppressor, Bcl-2
Both cytokines (Harrington et al., 1994) and Bcl-2 (Fanidi
et al., 1992) are effective at suppressing fibroblast apopto-
sis, which is most evident as a delay in onset of apoptosis,
with the extent of the delay depending upon levels expres-
sion of c-Myc and the abundance of IGF-1 or Bcl-2 (Evan
et al., 1992; Fanidi et al., 1992; Harrington et al., 1994). In-
triguingly, time-lapse videomicroscopic analysis reveals
that, while IGF-1 and Bcl-2 delay the onset of apoptosis
(as judged by the start of membrane blebbing), they do not
inhibit completion of the program once initiated. Cells
proceed from blebbing to final fragmentation within 20–60
min, essentially the same kinetics as cells cultured in the ab-
sence of IGF-1 or overexpression of bcl-2 (Fig. 7, A and B).
Figure 3. ZVAD.fmk delays the onset of characteristic markers
of apoptosis. (A) ZVAD.fmk delays destruction of mitochondrial
integrity. Rat-1/c-MycERÔ cells were plated into 96-well plates
in DME containing 10% FCS at a density of approximately 3,000
cells per well. After 48 h of culture, the medium was replaced
with serum-free medium and the cells left a further 48 h. Cells
were washed again, and the medium was replaced with either
growth medium containg 100 nM 4-OHT or 4-OHT plus
ZVAD.fmk, as indicated. Mitochondrial integrity was then as-
sayed at various times by a photometric MTT assay. Bars repre-
sent means of quadruplicate culture wells 6 SDs. Data shown are
from a single representative experiment. (B) Flow cytometric
analysis of Rat-1/c-MycERÔ cells undergoing c-Myc–induced ap-
optosis in cells in the presence or absence of ZVAD.fmk. At time
0, 4-OHT 6 ZVAD.fmk was added to serum-deprived cells. Cells
were then harvested, at time points indicated, by trypsinization.
Cells were fixed in ethanol, stained with propidium iodide, and
examined by flow cytometry. The sub-G1 peak characteristic of
apoptotic cells is absent from the ZVAD.fmk-treated popula-
tions.McCarthy et al. Inhibition of ICE-related Proteases and Apoptosis 221
Figure 4. ZVAD.fmk inhib-
its cleavage of known sub-
strates of ICE-related pro-
teases in Rat-1/c-MycERÔ
cells expressing activated
c-Myc in low serum. (A) Im-
munoblot analysis of cleav-
age of three known IRP sub-
strates in Rat-1/c-MycERÔ
cells in which c-Myc has been
activated in low serum in
the presence or absence of
ZVAD.fmk. (i) Inhibition of
cleavage of lamins A and C
by ZVAD.fmk. ZVAD.fmk
treatment inhibits the ap-
pearance of the characteristic
46-kD IRP cleavage product
in apoptosis (Oberhammer et
al., 1994) at both 24 and 48 h.
Lane 1, time-0 cells; lane 2,
24-h control cells; lane 3, 24-h
ZVAD.fmk-treated cells;
lane  4, 48-h control cells; lane
5, 48-h ZVAD.fmk-treated
cells. (ii) Inhibition of PARP
cleavage by ZVAD.fmk. IRP
cleavage of PARP produces
a characteristic 85-kD frag-
ment in apoptotic cells (La-
zebnik et al., 1994). In non–
ZVAD.fmk-treated Rat-1/c-
MycERÔ cells, the 85-kD
PARP fragment is visible by
24 h and further increased at
48 h. In the ZVAD.fmk-
treated cells, the 85-kD frag-
ment is absent at 24 h and
only faintly seen at 48 h. Lane
1, time-0 control cells; lane 2,
time-0 ZVAD.fmk-treated
cells; lane 3, 24-h control
cells; lane 4, 24-h
ZVAD.fmk-treated cells;
lane  5, 48-h control cells; lane
6, 48-h ZVAD.fmk-treated
cells. (iii) ZVAD.fmk inhib-
its actin cleavage in apoptotic
cells, characterized by the ap-
pearance of a 15-kD frag-
ment recognized by the anti-
body used. Appearance of
this fragment is inhibited by ZVAD.fmk. Lane 1, time-0 cells; lane 2, 48-h control cells; lane 3, 48-h ZVAD.fmk-treated cells; lane 4, 96-h
control cells; lane 5, 96-h ZVAD.fmk-treated cells. (B) Confocal immunofluorescence microscopy of distribution of known IRP sub-
strates. (i) Viable Rat-1/c-MycERÔ cells stained with anti–lamin A1C antibody demonstrate characteristic lamin staining in the nu-
clear periphery. In apoptotic cells, such staining is absent because of degradation and dispersal of lamins. In contrast, ZVAD.fmk-
treated blebbing cells exhibit near-normal lamin A1C staining when compared to controls. (ii) Rat-1/c-MycERÔ cells stained with
phalloidin-FITC to examine the distribution of actin. Viable cells exhibit normal actin fibers; apoptotic cells are condensed with no ac-
tin filaments visible. In ZVAD.fmk-treated cells, actin is clumped in blebs on the cell surface. Note that blebbing cells are markedly re-
duced in size compared with their viable counterparts. (iii) Both viable and blebbing Rat-1/c-MycERÔ cells exhibit nuclear PARP
staining, which is absent in apoptotic cells. Bars, 10 mm.The Journal of Cell Biology, Volume 136, 1997 222
This is consistent with the notion that Bcl-2, serum and
survival factors like IGF-I signaling act upstream of the
onset of membrane blebbing, effectively reducing the
probability that the apoptotic program will be initiated in
any individual cell. In complete contrast, ZVAD.fmk
acts downstream of membrane blebbing but before the
later stages of apoptosis. To investigate further the tem-
poral relationship between serum survival factors and
ZVAD.fmk inhibition of apoptosis, we induced blebbing
in ZVAD.fmk-treated Rat-1/c-MycERÔ cells by addition of
Figure 5. Electron microscopic analysis of apoptosis in serum-deprived Rat-1/c-MycERÔ cells in the presence and absence of
ZVAD.fmk. Electron microscopical analysis of individual Rat-1/c-MycERÔ cells undergoing 4-OHT–induced apoptosis in low serum.
(A) Normal, viable Rat-1/c-MycERÔ cells. (B) A typical apoptotic cell. (C and D) Early and late stages, respectively, of the morpholog-
ical changes where apoptosis is induced in the presence of ZVAD.fmk, showing dramatic cytoplasmic blebbing but absence of chroma-
tin condensation. Bars, 1 mm.McCarthy et al. Inhibition of ICE-related Proteases and Apoptosis 223
4-OHT in the absence of serum and then examined
whether readdition of serum could reverse the blebbing
phenotype and allow cell recovery. Cultures were ob-
served by time-lapse videomicroscopy. At the time serum
was added, some cells within the population had just be-
gun to bleb, whereas others had been blebbing for hours.
In none of .500 cells examined was there any reversal of
blebbing, and all cells that had initiated blebbing eventu-
ally went on to die. A study of a representative population
is depicted in Fig. 8. From examination of time-lapse video
data, it was also apparent that ZVAD.fmk-treated bleb-
bing cells do not proliferate. Of some 1,000 cells examined,
no division was ever observed of any cell that had started
blebbing. However, this is not due to a cytostatic effect of
ZVAD.fmk per se since nonapoptotic cells in ZVAD.fmk-
treated cultures divide at normal rates, as judged by time-
lapse videomicroscopy (see Note Added in Proof for Web
Information) and DNA profile (Fig. 3 B). Thus, we con-
clude the onset of blebbing is coincident with loss of clon-
agenic potential. Interestingly, cells that had not yet initi-
ated blebbing at the time of serum readdition remained
viable, never blebbed, and, in the presence of ZVAD.fmk,
proliferated to eventually repopulate the culture (not
shown). Thus, readdition of survival factors before the on-
set of membrane blebbing can completely protect both the
viability and proliferative potential of cells.
Finally, we asked whether ZVAD.fmk-blocked, bleb-
bing cells might be rescued by removal of 4-OHT from the
growth medium, thus inactivating c-Myc protein, which, in
the Rat-1/c-MycERÔ cells, is dependent upon the contin-
uous presence of 4-OHT (Littlewood et al., 1995). Of some
500 cells examined, we have observed no recovery of any
ZVAD.fmk-treated blebbing cell upon removal of 4-OHT
(data not shown), affirming the commitment of these cells
to eventual death.
Discussion
A cell suicide program appears to have arisen early in
metazoan evolution and been substantially conserved.
Two of the three principal genes directly involved in con-
trol and execution of ontogenetic cell death in the devel-
opmentally invariant nematode worm C. elegans, ced-9
and ced-3, encode polypeptides that have multiple mam-
malian homologues: the Bcl-2 (Hengartner and Horvitz,
1994) and ICE-related cysteine protease (Xue and Hor-
vitz, 1995) families, respectively. Both the Bcl-2 and IRP
families are implicated in vertebrate cell suicide, a process
Figure 6. Expression of cell surface phosphatidyl serine. ZVAD.fmk delays the emergence of annexin V binding. Serum-deprived Rat-1/c-
MycERÔ cells undergoing c-Myc–induced apoptosis in the presence or absence of ZVAD.fmk were examined by phase-contrast mi-
croscopy to determine their morphologies (a and c). FITC-labeled annexin V was then added to the culture dishes to a final concentra-
tion of 2.5 mg/ml, and the same cells were examined by fluorescence microscopy (b and d). In the absence of ZVAD.fmk, apoptotic cells
stain with annexin V (a and b). In contrast, ZVAD.fmk-treated blebbing cells do not bind annexin V (c and d).The Journal of Cell Biology, Volume 136, 1997 224
whose morphological manifestation is apoptosis. In con-
trast to C. elegans, however, cell suicide in vertebrates is
influenced by many diverse factors that include extracellu-
lar signals, genotoxic and physical trauma, anoxia, onco-
gene expression, and immune killing. How all of these dif-
fering agents impact upon the underlying cell death
mechanism is unclear. Specifically, it is unclear which of
the factors that modulate vertebrate cell death are part of
the actual execution machinery—the mechanism that
physically dismantles the cell—and which are merely regu-
latory mechanisms that govern the engagement of the exe-
cution process.
The best candidates for components of the execution
machinery of vertebrate apoptosis are the Ced-3 homo-
logues, the ICE-related proteases. Consistent with this,
many diverse studies implicate IRPs in apoptosis induced
by insults such as growth factor deprivation (Milligan et al.,
1995; Nicholson et al., 1995), loss of contact with extracel-
lular matrix (Boudreau et al., 1995), Fas/TNF (Enari et al.,
1995; Los et al., 1995; Duan et al., 1996a; Schlegel et
al., 1996), and cytotoxic T cell killing (Darmon et al.,
1995). We have therefore investigated the requirement of
IRPs in mammalian apoptosis using the IRP inhibitors
ZVAD.fmk and BD.fmk. ZVAD.fmk and BD.fmk are
particularly useful inhibitors for studying IRP action in in-
tact cells because their intrinsic hydrophobicity permits
their entry into cells, whereupon intracellular esterases
convert the aspartyl methyl ester to aspartate to generate
irreversible inhibitors of IRPs. Both ZVAD.fmk and
BD.fmk have been shown to be effective inhibitors of apop-
tosis in intact cells with broad reactivities amongst tested
ICE family proteases (Fearnhead et al., 1995; Slee et al.,
1996). In our studies, we observed no differences in effect
between ZVAD.fmk and BD.fmk. Consequently, most of
the data we show is confined to studies with just one of
these inhibitors, ZVAD.fmk.
We investigated the ability of ZVAD.fmk to inhibit apop-
tosis triggered by diverse promoters of apoptosis: c-Myc
and E1A oncogene expression, DNA damage induced by
the topoisomerase II inhibitor etoposide, and ectopic ex-
pression of the killer member of the Bcl-2 family Bak. In
all cases, ZVAD.fmk provided substantial protection from
apoptosis that correlated with inhibition of cleavage of the
known IRP substrates, actin, lamins, and PARP. Thus, on-
cogenes, p53 (after DNA damage), and pro-apoptotic
members of the Bcl-2 family all induce apoptosis via a
ZVAD.fmk-sensitive activity, most probably one or more
IRPs. These findings extend the critical role of IRPs in
mammalian apoptosis to include stimuli of fundamental
importance in the genesis and progression of neoplasia.
However, detailed time-lapse videomicroscopic analysis
of cells protected by ZVAD.fmk revealed an unexpected
and novel phenotype. An early manifestation of apoptosis
in most cells is the onset of vigorous membrane blebbing.
Membrane blebbing is a well-described characteristic of
apoptosis in many cell types that, in the normal course of
apoptosis in fibroblastic cells, is rapidly (20–60 min) fol-
lowed by cell shrinkage, chromatin condensation, and nu-
clear and cellular fragmentation. Surprisingly, in cultures
of ZVAD.fmk-treated cells induced to initiate apoptosis
by the action of c-Myc, E1A, or Bak or the genotoxic
agent etoposide, we found that the onset of membrane
blebbing was not delayed by the presence of ZVAD.fmk
in the culture medium. However, whereas untreated
blebbing apoptotic cells rapidly proceed through the latter
stages of chromatin condensation and cell fragmentation,
ZVAD.fmk-treated cells continue to bleb vigorously for
greatly extended periods of time, typically several days.
Such blebbing cells exhibit few characteristics of apoptotic
cells: cell nuclei remain intact with little evidence of chro-
matin condensation or nuclear fragmentation, plasma
membrane integrity and mitochondrial function are pre-
served, and phosphatidylserine is not expressed on the cell
surface. Thus, ZVAD.fmk appears not to inhibit the onset
of membrane blebbing, although it effectively suppresses
classical late-stage apoptotic events.
Figure 7. IGF-I and Bcl-2 delay the initiation of the apoptotic program but not its execution. Serum-deprived Rat-1/c-MycERÔ cells
were treated with 100 nM 4-OHT to activate c-Myc, and this was followed by time-lapse videomicroscopy. Onset of apoptosis was
scored at the start of blebbing. End points of cell death were scored at the point of cell detachment, and the time between these two is
represented by the length of the horizontal line. (A) Apoptotic events in the presence or absence of IGF-1. The effect of IGF-1 on the
kinetics of Myc-induced apoptosis. (B) The effect of Bcl-2 expression on the kinetics of Myc-induced apoptosis. Apoptotic events in the
presence or absence of co-expressed Bcl-2.McCarthy et al. Inhibition of ICE-related Proteases and Apoptosis 225
Moreover, although ZVAD.fmk substantially amelio-
rates the pro-apoptotic effects of c-Myc, DNA damage,
and Bak in Rat-1 fibroblasts, most cells nonetheless do
eventually detach from the substratum. Such cells exhibit
some chromatin condensation (although far less than in
normal late-stage apoptotic cells) but preserve intact nu-
clear lamina; they also have extensively fragmented and
vacuolated cytoplasm. Eventually, however, late-stage
ZVAD.fmk-treated  cells  lose their integrity and take up
vital dyes—indisputable evidence of their ultimate death. We
conclude that late-stage ZVAD.fmk-treated cells undergo a
delayed “partial” apoptotic process, although a more de-
tailed characterization of these late-stage cells will be re-
quired to establish their precise phenotype. We have in-
vestigated whether the delay to cell death afforded by
ZVAD.fmk might be extended either by addition of
higher initial concentrations of ZVAD.fmk to the growth
medium or by its repeated readdition. However, neither
alters the kinetics of cell death within Rat-1 cell cultures. It
is difficult to assess the significance of this observation be-
cause of uncertainty as to the effective intracellular con-
centration of ZVAD.fmk administered to culture medium,
or of the inhibitor’s half-life in culture media or within
cells. Nonetheless, it is possible that a continued pro-apop-
totic stimulus eventually overrides the ZVAD.fmk block
or bypasses the ZVAD.fmk-sensitive components of the
apoptotic program.
Why should apoptotic cells exhibit prolonged blebbing
when treated with ZVAD.fmk? One possibility is that the
blebbing we observe in ZVAD.fmk-treated cells is differ-
ent from the normal blebbing that accompanies apoptosis
and has nothing to do with apoptosis. Three factors argue
against this. By time-lapse videomicroscopy and light and
electron microscopy, the blebbing observed in the pres-
ence of ZVAD.fmk appears identical to that seen in con-
trol cells undergoing normal apoptosis. In addition, the
onset of blebbing in ZVAD.fmk-treated cell populations is
identical to that in control populations; it merely continues
for far longer as it is not accompanied by cell and nuclear
fragmentation. Finally, time-lapse videomicroscopy shows
that blebbing ZVAD.fmk-treated cells adhere to live cells
in the same way as true apoptotic bodies (Whyte, M., N.
McCarthy, and G.I. Evan, unpublished data) (see Note
Added in Proof for Web Information), indicating that at
least some of the pro-phagocytic processes triggered dur-
ing normal apoptosis (although not surface display of
phosphatidylserine) also occur in ZVAD.fmk-blocked
cells. A second possibility is that ZVAD.fmk fails to pre-
vent membrane blebbing because blebbing is not part of
the basal apoptotic program but merely a dispensable
epiphenomenon that commonly accompanies the process.
However, the notion that membrane blebbing is not part
of apoptosis is difficult to reconcile with our time-lapse
videomicroscopic data, which show that once blebbing is
initiated, it is not reversed by the action of antiapoptotic
cytokines or by removal of the original pro-apoptotic trig-
ger. Thus, blebbing appears to be concomitant with com-
mitment to death. We also dislike this explanation because
it seeks to explain the ZVAD.fmk phenotype by redefin-
ing apoptosis so as to exclude a characteristic of the pro-
cess that is so unique and ubiquitous as to give the phe-
nomenon its name. A third possibility is that membrane
blebbing is part of the bona fide apoptotic process but trig-
gered by IRPs that are not inhibited by ZVAD.fmk. This
possibility needs to be investigated using a range of IRP
inhibitors with differing spectrums of specificity. However,
at present the possibility remains that membrane blebbing
is triggered by a completely different mechanism that
might not involve IRP action at all.
The phenotype of continuous membrane blebbing that
we observe in ZVAD.fmk-treated apoptotic cells appears
to contradict several reports that indicate that chemical
and viral IRP inhibitors can afford long term protection
against apoptosis. For example, peptide and viral inhibi-
tors of IRPs protect motor neurons against apoptosis after
factor withdrawal (Gagliardini et al., 1994; Martinou et al.,
1995; Tewari et al., 1995), protect cells from Fas and TNF-
induced killing (Beidler et al., 1995; Enari et al., 1995,
1996; Los et al., 1995), and block developmental apoptosis
in Drosophila (Hay et al., 1995) and C. elegans (Xue and
Horvitz, 1995). In some of these instances, it is possible
that the protected cells have nonetheless initiated a mem-
brane blebbing program that is not easily discernible using
Figure 8. Serum survival factors do not rescue ZVAD.fmk-
blocked apoptotic cells once they have initiated blebbing. Apop-
tosis was induced in serum-deprived Rat-1/c-MycERÔ fibro-
blasts by addition of 4-OHT, and cells were observed by time-
lapse videomicroscopy. 40 h after addition of 4-OHT, FCS was
added back to the growth medium to a final concentration of
10%. Cells that had initiated membrane blebbing were then fol-
lowed to determine their fates. The figure shows a representative
study of 18 independent cells fates. Initiation of membrane
blebbing (d) and death of the cell (|) were determined as before,
and the time interval between the two is given by the horizontal
line. All cells that initiated membrane blebbing before serum re-
addition eventually died. In contrast, all observed cells that had
not yet initiated blebbing at the time of serum readdition sur-
vived and went on to divide (not shown).The Journal of Cell Biology, Volume 136, 1997 226
static imaging techniques. Furthermore, it is possible that
blebbing cells remain capable of sustaining some of the
functions of normal living cells within the soma, at least
temporarily. In other situations, cell death may be trig-
gered by directly activating or recruiting IRPs, in which
case inhibiting IRP activity might be sufficient to prevent
completely all manifestations of apoptosis. For example,
the DEVD-specific IRP CPP32b is directly cleaved and
activated by the cytotoxic T cell granule serine esterase
Granzyme B and both the CD95 and TNF-R1 cytotoxic
signaling pathways directly recruit (and presumably acti-
vate) the IRP FLICE/MACH via their “Death Domains”
(Boldin et al., 1996; Muzio et al., 1996). By inference, the
Drosophila Reaper, another Death-Domain protein, may
act similarly to recruit directly downstream IRPs during
developmental apoptosis in the fly. In the cases of onco-
gene deregulation, DNA damage/p53, and Bak, our data
indicate that all these triggers of apoptosis act on some up-
stream regulator that can independently activate both
IRPs and membrane blebbing.
By time-lapse videomicroscopic analysis, we observe a
clear difference in the anti-apoptotic actions of the IRP in-
hibitor ZVAD.fmk, on the one hand, and the well-charac-
terized antiapoptotic factors Bcl-2 and IGF-I, on the
other. The actions of both Bcl-2 and IGF-I are to lower the
probability of initiation of the apoptotic program, but nei-
ther has any effect on the kinetics of each apoptotic event
(as defined as the time from onset of blebbing to cell frag-
mentation) once initiated. In complete contrast, ZVAD.fmk
does not inhibit initiation of the apoptotic program, as
judged by the onset of membrane blebbing, but prolongs
each individual apoptotic event by inhibiting the cellular
fragmentation that normally rapidly ensues. Importantly,
cells that have initiated membrane blebbing but are blocked
in completion of the apoptotic program by ZVAD.fmk
cannot be rescued by the action of antiapoptotic survival
factors and thus appear to be beyond a point of commit-
ment to die. In addition, ZVAD.fmk-blocked blebbing cells
do not divide; they have no clonagenic potential and from
the stance of their neoplastic potential may therefore be
considered as “genetically dead.” The clear implication from
this is that, unlike more upstream inhibitors of apoptosis
like Bcl-2 and survival factors, IRP inhibitors (whether vi-
ral or chemical) will not act as generic carcinogens because
they inhibit the apoptotic program downstream of an irre-
versible point where replicative potential is lost.
In conclusion, we have shown that oncogene deregula-
tion, DNA damage, and expression of the Bcl-2 family
member Bak all induce apoptosis in mammalian fibro-
blasts via a ZVAD.fmk-inhibitable mechanism, probably
one or more IRP. Nonetheless, time-lapse videomicro-
scopic analysis clearly distinguishes between the antiapop-
totic actions of Bcl-2 or the survival factor IGF-I on the
one hand and IRP inhibition on the other. Both Bcl-2 and
IGF-I signaling act to suppress initiation of the apoptotic
program, yet have no effect on the kinetics of each apop-
totic event. In contrast, ZVAD.fmk has no effect on initia-
tion of apoptosis, as determined by membrane blebbing,
but acts to arrest each apoptotic program before comple-
tion. This observation raises the intriguing possibility that
membrane blebbing is a discrete subprogram operating
during mammalian apoptosis that can lead to cell death via
an IRP-independent mechanism. If true, this will constrain
the potential therapeutic use of IRP inhibitors. However,
such speculations can only be validated by the develop-
ment of specific inhibitors for each IRP and a more de-
tailed understanding of the intracellular targets and kinet-
ics of these enzymes.
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Note Added in Proof. Quick-Time movies showing c-Myc–induced apop-
tosis in the absence of serum (Movie One) and c-Myc–induced apoptosis
in the absence of serum and the presence of 100 mM zVAD.fmk, the
blebbing phenotype (Movie Two), are available from the following Web
site address: http://www.icnet.uk/axp/bcn/
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